VTYX News and Press, Ventyx Biosciences Inc. From 08/10/23

Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2023 Initiated a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, in adu...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced t...

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announ...

2023-07-03 14:09:59 ET On Monday, shares of Ventyx Biosciences (NASDAQ: VTYX) closed 22.87% higher than they did last week. The clinical-stage biotech hit more than $40 a share for the first time since March 10. Ventyx focuses on therapies to treat inflammatory diseases and ...

2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...

2023-06-15 17:30:08 ET Summary Ventyx Biosciences, Inc. has a number of interesting assets in mid-stage trials. The company is founded by a successful serial entrepreneur. Phase 2 data later this year will be pivotal for Ventyx Biosciences prospects. Using a new and ...

ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, toda...

2023-06-08 23:10:34 ET Summary Dan Loeb's Third Point increased its 13F portfolio value to $6.11B in Q1 2023, with top three holdings accounting for around 41% of the entire portfolio. New stakes were established in Alphabet Inc., HCA Healthcare, Salesforce, and Alibaba Group Hold...

ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, toda...

2023-05-14 13:55:03 ET Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Conference Call May 11, 2023 04.30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief M...